FDA Grants Breakthrough Status to Innate Pharma’s Lacutamab for Sézary Syndrome Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that the U.S. FDA has…
U.S. FDA Fully Approves Deciphera’s ROMVIMZA™ for TGCT Treatment Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) has announced that the U.S. Food and Drug Administration (FDA)…
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Updates Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company dedicated to developing innovative…
European Commission Approves KOSTAIVE®, the First Self-Amplifying mRNA COVID-19 Vaccine Global biotechnology leader and self-amplifying mRNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT) have announced that the European Commission (EC) has…
OS Therapies Initiates Commercial-Ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Application (BLA) Filing OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company dedicated to advancing immunotherapies and targeted…
Galderma (SWX:GALD) has announced that the European Commission has granted approval for Nemluvio, a groundbreaking biologic therapy, for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis within the European…
GeneDx Introduces ultraRapid Whole Genome Sequencing for NICU and PICU Patients, Offering Actionable Results in Just 48 Hours GeneDx (Nasdaq: WGS), a leading provider of genomic insights to improve health…
Tempus Partners with IFLI to Advance Development of Targeted Therapies for Follicular Lymphoma Tempus AI, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Join Forces to Accelerate Development of…
Junevity Secures $10M to Advance Cell Reset Therapies for Longevity Junevity Secures $10M in Seed Funding to Develop Cell Reset Therapies Targeting Age-Related Diseases Junevity, a forward-thinking biotechnology company focused…
Quantum-Si and Leading Researchers to Showcase Advances in Next-Generation Protein Sequencing™ at US HUPO 2025 Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI,” or “the Company”), renowned as The Protein Sequencing Company™,…
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company focused on developing targeted oncology therapies and commercializing the FDA-cleared RenovoCath device, recently showcased its latest pre-clinical data…
Newleos Launches with $93.5M to Advance Neuropsychiatric Treatments Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and experienced leaders in CNS drug development, has announced the successful…